Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record.

Safety and efficacy of botulinum toxin type A following long‐term use

Naumann, M., Albanese, A., Heinen, F., Molenaers, G., Relja, M. · 2006 · European Journal of Neurology

Abstract

Botulinum toxin serotype A (BoNT‐A) has long heritage of use leading to confidence in its safety and efficacy. The application of BoNT‐A does not lead to persistent histological changes in the nerve terminal or the target muscle. Clinical trials defined the safety and tolerability profile of BoNT‐A across common therapeutic indications and showed an incidence of adverse events of approximately 25% in the BoNT‐A‐treated group compared with 15% in the control group. Focal weakness was the only adverse event to occur more often following BoNT‐A treatment. Long‐term BoNT‐A administration has been assessed in various treatment settings, with the level and duration of BoNT‐A efficacy response being maintained over repeated rounds of injection with no major safety concerns. The treatment of children with cerebral palsy often require long‐term, repeated, multimuscle BoNT‐A injections that lead to the administration of comparably higher toxin doses. Despite the high total body doses used, their distribution over multiple muscles and injection sites means that systemic side effects are rare. Recent formulation changes have reduced the incidence of antibody development following treatment with BOTOX®. These findings show long‐term BoNT‐A treatment to be both safe and efficacious for a wide variety of indications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1468-1331.2006.01652.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 169

Metadata

Authors
Naumann, M., Albanese, A., Heinen, F., Molenaers, G., & Relja, M.
Venue
European Journal of Neurology
Publisher
Wiley
Published
2006-11-13
Volume
13
Issue
s4
Pages
35-40
ISSN
  • 1351-5101 (ISSN-L)
  • 1468-1331
OpenAlex
W2162210794
Cited by
169
References
0
FWCI
5.44
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of botulinum toxin type A following long‐term use. https://app.cochat.ai/papers/10.1111/j.1468-1331.2006.01652.x
The paper
Naumann, M., Albanese, A., Heinen, F., Molenaers, G., & Relja, M. (2006). Safety and efficacy of botulinum toxin type A following long‐term use. European Journal of Neurology. https://doi.org/10.1111/j.1468-1331.2006.01652.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.